ArticleAIDS and behavior2018
Barriers and Facilitators to Oral PrEP Use Among Transgender Women in New York City.
Article in AIDS and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05262426 (Optimizing an mHealth Intervention to Improve Uptake and Adherence of the HIV Pre-exposure Prophylaxis), which is not on this map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing an mHealth Intervention to Improve Uptake and Adherence of the HIV Pre-exposure Prophylaxis (PrEP) in Vulnerable Adolescents and Emerging Adults
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- Barriers and Facilitators Influencing PrEP Uptake Among Men Who Have Sex with Men and Transgender Women in the United States: A Systematic Review.AIDS and behavior · 2026Pooled it
- A Systematic Review and Narrative Synthesis of Factors Affecting Pre-exposure Prophylaxis Willingness Among Black Women for HIV Prevention.AIDS and behavior · 2025Pooled it
- Adverse effects of daily oral pre-exposure prophylaxis in men who have sex with men and transgender women: a systematic review and meta-analysis.Cadernos de saude publica · 2023Pooled it
- Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review.AIDS patient care and STDs · 2022Pooled it
- Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.The lancet. HIV · 2023Trial
- The Role of Healthcare-Related Experiences in Willingness and Preference for Long-Acting Injectable PrEP (LAI-PrEP) Among Transfeminine People in the United States.AIDS and behavior · 2026Article
- PrEP and PEP: awareness, use, and preferences among Latina immigrant transgender women in the Washington DC metropolitan area.AIDS care · 2026Article
- Special Issue: New Horizons in HIV and Reproductive Health Research: HIV Acquisition and Reproductive Health in Key Populations.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Pre-Exposure Prophylaxis Adherence and HIV Self-Testing App Among Women in the South Bronx: 12-Month Usability, Acceptability, and Feasibility Study.JMIR formative research · 2026Article
- Review
- Barriers and Facilitators of Oral PrEP Uptake Against HIV Among Selected Priority Populations: A Global Perspective.Current HIV/AIDS reports · 2026Review
- HIV Preexposure Prophylaxis Utilization and Reasons for Never Using Preexposure Prophylaxis Among Transfeminine Persons in the United States: Findings From the Transgender Women's Internet Survey and Testing (TWIST) Study.Open forum infectious diseases · 2026Article
- Article
- Beyond Prevention: How Gender-Affirming Care Can Transform HIV Outcomes for Transgender and Gender-Diverse Populations.American journal of public health · 2025Article
- High Preference for Injectable Pre-exposure Prophylaxis among Young Women in Kenya.AIDS and behavior · 2025Article
- Awareness and intention to use event-driven and long-acting injectable pre-exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross-sectional study.Journal of the International AIDS Society · 2025Article
- Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort.AJPM focus · 2025Article
- Multi-Level and Intersectional Stigma Experienced by Black Transgender Women in Chicago: a Qualitative Study to Inform Sociostructural Interventions for Reducing Stigma and Improving Health Outcomes.Journal of racial and ethnic health disparities · 2025Article
- Article
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Transgender women may face a disparate risk for HIV/AIDS compared to other groups. In 2012, Truvada was approved for daily use as HIV pre-exposure prophylaxis (PrEP). However, there is a dearth of research about barriers and facilitators to PrEP in transgender women. This paper will shed light on transgender women living in New York City's perceived and actual challenges to using PrEP and potential strategies to overcome them. After completing an initial screening process, four 90-min focus groups were completed with n = 18 transgender women. Participants were asked what they like and dislike about PrEP. Participants identified the following barriers: uncomfortable side effects, difficulty taking pills, stigma, exclusion of transgender women in advertising, and lack of research on transgender women and PrEP. Facilitators included: reducing pill size, increasing the types of available HIV prevention products, and conducting scientific studies to evaluate PrEP in transgender women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.